Post-Market Clinical Follow-Up Study to Provide Safety, Performance and Clinical Benefits Data of the RingLoc Bipolar Acetabular Cup or Endo II Heads (Implants and Instrumentation) in Hip Hemiarthroplasty - A Retrospective Enrollment/Prospective Follow-Up Consecutive Series Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Hip Arthritis
- Sponsor
- Zimmer Biomet
- Enrollment
- 116
- Locations
- 1
- Primary Endpoint
- Device safety assessed through the frequency and incidence of revisions, complications, and Adverse Events.
- Status
- Not yet recruiting
- Last Updated
- 5 months ago
Overview
Brief Summary
The objective of this retrospective enrollment/prospective follow-up consecutive series PMCF study is to collect data confirming safety, performance, and clinical benefits of the RingLoc Bipolar Acetabular Cup and the Endo II Femoral Head when used for hip hemiarthroplasty (implants and instrumentation).
Detailed Description
The objective of this retrospective enrollment/prospective follow-up consecutive series PMCF study is to collect data confirming safety, performance, and clinical benefits of the RingLoc Bipolar Acetabular Cup and the Endo II Femoral Head when used for hip hemiarthroplasty (implants and instrumentation). The primary objective of this study is the assessment of safety by analyzing implant survivorship at the longest follow-up timepoint available, greater than or equal to eight years post-implantation. This will be established by recording the incidence and frequency of revisions, complications, and adverse events. Relationship of the events to implant, instrumentation and/or procedure should be specified. The secondary objective is the assessment of performance and clinical benefits by recording patient-reported clinical outcomes measures (PROMs).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patient must be 18 years of age or older and skeletally mature
- •Patient must have undergone hip hemiarthroplasty surgery with the RingLoc Bipolar Acetabular Cup or Endo II Femoral Head for a cleared indication, greater than or equal to eight years previous to the date of study consent. Cleared indications for the RingLoc Bipolar and Endo II Heads include the following:
- •Noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis
- •Rheumatoid arthritis
- •Correction of functional deformity
- •Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable using other techniques.
Exclusion Criteria
- •Any medical diagnosis present at the time of surgery that, at the Investigator's discretion, could compromise the implant's survivability
- •Off-label use or not according to the approved instructions for use (IFU) of study devices
- •Revision procedures where other treatment or devices have failed
- •Uncooperative patient or patient with neurologic disorders who is incapable of following directions
- •Patient has a psychiatric illness or
Outcomes
Primary Outcomes
Device safety assessed through the frequency and incidence of revisions, complications, and Adverse Events.
Time Frame: Greater than or equal to 8 years.
The primary objective of this study is the assessment of safety by analyzing implant survivorship. This will be established by recording the incidence and frequency of revisions, complications, and Adverse Events. Relation of the events to either implant or instrumentation will be specified.
Secondary Outcomes
- Device Performance and Benefits evaluated through the Oxford Hip Score and Patient Assessment.(Greater than or equal to 8 years.)